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Abstract: Heat-stable toxins (STs) produced by enterotoxigenic bacteria cause endemic 
and traveler’s diarrhea by binding to and activating the intestinal receptor guanylyl 
cyclase C (GC-C). Advances in understanding the biology of GC-C have extended ST from 
a diarrheagenic peptide to a novel therapeutic agent. Here, we summarize the physiological 
and pathophysiological role of GC-C in fluid-electrolyte regulation and intestinal  
crypt-villus homeostasis, as well as describe translational opportunities offered by STs, 
reflecting the unique characteristics of GC-C, in treating irritable bowel syndrome and 
chronic constipation, and in preventing and treating colorectal cancer. 
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antigens; CNG: cyclic nucleotide-gated channel; COX-2: cyclooxygenase-2;  
GC-C: guanylyl cyclase C; IBD: inflammatory bowel disease; IBS: irritable bowel 
syndrome; MRP: multidrug resistance proteins; PDE: phosphodiesterase;  
PGE: prostaglandin; PKA: cAMP-dependent protein kinase; PKG: cGMP-dependent 
protein kinase; PLA2: phospholipase A2; pRb: phosphorylated retinoblastoma;  
SBM: spontaneous bowel movement; ST: heat-stable enterotoxin 
 
1. Introduction 
1.1. Bacterial heat-stable enterotoxins 
Bacterial heat-stable enterotoxins (STs) first came to attention in the 1970s after heat-inactivation 
of cultures of bacteria isolated from patients suffering from diarrhea failed to eliminate enterotoxigenic 
activity [1,2]. Two families of heat-stable enterotoxins have been identified: STa (or STI) and STb  
(or STII), which differ by their physicochemical and biologic characteristics [1,3]. Although STa and STb 
were both discovered in intestinal bacterial strains isolated from humans, STb is produced by bacterial 
strains that preferentially inhabit pigs [4]. Further, STa induces diarrhea through a cyclic nucleotide-
dependent mechanism, while STb induces secretion through a cyclic nucleotide-independent mechansim 
[5]. STa, hereon referred to as ST, will be the only heat-stable enterotoxin discussed in this review. 
STs are produced by a variety of enteric pathogenic organisms, including diarrheagenic 
Escherichia coli (E. coli), Vibrio cholerae, Vibrio mimicus, Yersinia enterocolitica, Citrobacter freundii, 
and Klebsiella pneumoniae [1,2,6–10]. STs are translated as precursor peptides, which undergo 
intracellular proteolytic processing to active peptides from 17 to 53 amino acids [11]. Isoforms of ST 
share a conserved C-terminal region of 13 amino acids containing three disulfide bonds responsible for 
heat stability and biological activity (Figure 1)[11]. Consistent with the proposed function of ST as an 
essential survival factor facilitating escape of bacteria from nutrient-poor to nutrient-rich 
environments, synthesis and secretion of ST is reduced in a milieu enriched in glucose while depletion 
of this sugar stimulates ST production and secretion [12,13]. Investigation of the pathogenesis 
underlying diarrhea produced by ST ultimately revealed two intestinal paracrine hormones, guanylin 
and uroguanylin, and the receptor for these homologous peptides, guanylyl cyclase C (GC-C), encoded 
by the gene GUCY2C [14]. 
1.2. Molecular mimicry, convergent evolution and the guanylyl cyclase C paracrine hormone axis 
Guanylyl cyclase C (GC-C), the only identified receptor for ST, belongs to the guanylyl cyclase 
family of receptors that catalyze the conversion of GTP to cGMP upon activation [14]. Guanylyl 
cyclases are found in two subcellular compartments in mammalian cells: soluble guanylyl cyclases (sGC) 
are completely intracellular and particulate guanylyl cyclases (pGC), also known as receptor-linked 
guanylyl cyclase, span the plasma membrane [14]. GC-C is one of the seven isotypes of particulate 
guanylyl cyclases (GCA to GCG) that exhibit conserved domain structures including an extracellular 




ligand binding domain, a single transmembrane domain, an intracellular kinase homology domain, and 
a catalytic domain that produces cGMP [14].  
GC-C is primarily expressed in intestinal mucosal cells from the duodenum to the rectum [15,16] 
where it exists as a pre-formed homo -dimer or -trimer [17] located within apical membranes of 
epithelial cells populating the crypt-villus axis. The two defined endogenous ligands of GC-C, the 
hormones guanylin and uroguanylin, share significant homology with ST (Figure 1)[18,19]. Similar to 
ST, the tertiary structure of these peptides is stabilized by intra-chain disulfide bonds, which are 
essential for biological activity [20–22]. Additionally, guanylin and uroguanylin also are synthesized 
as pro-peptides [23], but unlike ST, these endogenous peptides undergo proteolytic processing 
following secretion [22,24,25]. These considerations suggest that ST and enterotoxigenic diarrhea are 
prime examples of molecular mimicry and convergent evolution. Here, bacteria have co-opted a 
normal mammalian physiologic function, the regulation of intestinal fluid and electrolyte homeostasis, 
to produce an evolutionary population survival scheme that guarantees the adequacy of nutrient 
resources and dissemination into new environments and hosts. 
Figure 1. Bacterial heat-stable enterotoxin, guanylin and uroguanylin. (A) Primary 
structures of heat-stable enterotoxins produced by various pathogenic bacteria and human 
homologs, guanylin and uroguanylin. Conserved core regions are highlighted (blue for 
STs; pink for hormones) with disulfide bridges indicated; (B) Three-dimensional structures 
of E. coli STa (grey), guanylin (purple) and uroguanylin (pink) conserved regions.  
Non-conserved regions in uroguanylin are labeled in yellow. Cysteines linked by disulfide 
bonds conserved among three peptides are colored in cyan. Cysteines linked by the  
extra-disulfide bond, providing ST greater potency than guanylin and uroguanylin, are 
colored in blue. 
 




1.3. Guanylyl cyclase C and enterotoxin signaling circuits 
Activation of GC-C stimulates a rise in intracellular cGMP, which binds and activates its three 
downstream effectors [17]: cGMP-dependent protein kinases (PKGs), phosphodiesterases (PDEs) and 
cyclic nucleotide-gated (CNG) channels. High intracellular levels of cGMP can also cross-activate 
cAMP-dependent protein kinases (PKA)[26]. PKGs are the principle intracellular mediators for cGMP 
signaling [27]. PKG is expressed in nearly all tissues, with highest expression in lung, cerebellum, 
smooth muscle, platelets, and intestinal mucosa [28,29]. PKG consists of two distinct isoforms: PKG 
type I and type II. PKG I is located within the cytoplasm of most cell types, whereas PKG II is 
exclusively expressed within plasma membranes in bone, kidney, brain, and intestine [28–31]. Within the 
intestinal epithelium, PKG II displays a rostral-caudal gradient of expression, with highest levels 
found in small intestine and lowest levels found in the distal colon. Intestinal PKG II expression also 
displays a crypt-villus gradient with highest expression in the villi and lowest expression in crypts 
[32]. Two closely related PKG I isoforms (type I and I), which arise from alternative splicing of the 
N-terminal region of the PKG I gene have been purified, cloned, and expressed [33–38]. Type I and 
type II PKG isoforms are homodimers of ~75 and 86 kDa monomers, respectively, consisting of (1) an 
N-terminal domain regulating kinase autoinhibition, autophosphorylation and subcellular localization; 
(2) regulatory domains with allosteric cGMP binding sites and (3) catalytic domains catalyzing the 
transfer of the γ-phosphoryl group of ATP to various protein substrates [39]. Beyond the primary 
signal carrying and amplification capacity of PKGs, cGMP signals also are shaped by PDEs, which 
degrade cGMPs to 5’ GMPs, and multidrug resistance proteins (MRPs), which are ATP-dependent 
active transporters pumping out cGMP. These enzymes maintain intracellular cGMP concentrations 
within a narrow physiologic range, essentially serving as key terminators of guanylyl cyclase 
signaling [40]. 
2. Enterotoxin Signaling, Irritable Bowel Syndrome and Chronic Constipation 
2.1. Enterotoxins, GC-C and fluid-electrolyte homeostasis 
Maintenance of fluid and electrolyte homeostasis is critical for cellular biochemical processes and 
organ function, and the intestine is one of the major organs controlling this balance. Discovery of the 
role of GC-C in fluid-electrolyte homeostasis is attributed to the observation that ST is a principal 
cause of enterotoxigenic diarrheal disease in humans and animals worldwide [38–40]. Physiologically, 
guanylin and uroguanylin regulate intestinal fluid and electrolyte homeostasis through cGMP 
accumulation, which activates PKGII leading to the phosphorylation of the cystic fibrosis 
transmembrane conductance regulator (CFTR), producing Cl-, HCO3-, and water secretion [14]. ST 
induces secretory diarrhea by exploiting this physiologic mechanism, and the enhanced affinity of ST 
for GC-C produces supra-physiologic induction of cGMP accumulation and extensive water and 
electrolyte secretion (Figure 2)[14,41,42]. Notably, systemic fluid and electrolyte homeostasis is 
maintained beyond intestine. The natriuretic and diuretic effects induced by uroguanylin and guanylin 
in the kidney still remain intact in GC-C deficient mice [43,44]. Therefore, GC-C-deficient mice do 
not exhibit significant systemic fluid-electrolyte imbalance [45].  




Figure 2. GC-C signaling for fluid/electrolyte secretion, inflammation, gut motility, and 
nociception. GC-C is activated by binding of bacterial heat-stable enterotoxins (STs) or the 
endogenous ligands, guanylin and uroguanylin. Ligand binding to the extracellular domain 
of GC-C activates the intracellular catalytic domain converting GTP to cGMP. Intracellular 
cGMP accumulation leads to fluid and electrolyte secretion through direct activation of 
cGMP-dependent protein kinase II (PKG II) and downregulation of phosphodiesterase 
(PDE)-driven cAMP hydrolysis leading to increased activation of cAMP-dependent 
protein kinase (PKA). PKG II and PKA phosphorylate the cystic fibrosis transmembrane 
conductance regulator (CFTR) producing channel opening, leading to an efflux of Cl− ions 
and secondary efflux of water. Intracellular cGMP accumulation also decreases  
pro-inflammatory signaling by inhibiting phospholipase A2, decreasing the liberation of 
the leukotriene (LT) and prostaglandin (PG) precursor, arachidonic acid, from membrane 
phospholipids. GC-C activation also enhances intestinal myoelectric activity and decreases 
afferent pain fiber firing, presumably through the release of specific soluble mediators, 
which stimulate surrounding dendritic nerve endings and alter neuronal firing rates. 
 
2.2. Enterotoxins and irritable bowel syndrome 
Besides enhancing gut fluid and electrolyte secretion, infections with enterotoxigenic bacteria, 
including V. cholerae and E. coli, alter gut motility [46–48], and administration of enterotoxins 




produced by these bacteria, including STs, stimulate intestinal myoelectric activity [46,49,50]. Indeed, 
downstream effects of ST signaling are mediated, in part, by stimulation of the enteric nervous system. 
Mechanical (vagotomy) or neuropharmacological (tetrodotoxin, lidocaine, etc.) disturbance of enteric 
neuronal activation, as well as antagonism of gut acetylcholine, serotonin, prostaglandin, and nitric 
oxide signaling, significantly reduces ST-induced GI secretion [51–57]. While the mechanism by 
which ST signaling stimulates enteric neurons is still unclear, GC-C activation by STs in apical 
epithelial cells may release specific mediators, which stimulate surrounding nerve endings and alter 
neuronal firing rates (Figure 2)[58,59]. 
Due to its ability to induce secretion and enhance gut motility, pharmacological modulation of GC-C 
signaling has been investigated as a possible treatment paradigm for chronic constipation and 
constipation-predominant irritable bowel syndrome (IBS-C). Irritable bowel syndrome (IBS) is a 
functional bowel disorder, which is associated with abdominal pain and altered bowel activity. Unlike 
inflammatory bowel disease (IBD), IBS is not associated with increased inflammation or other 
pathologic organic changes within the GI tract [60]. Rather, a diagnosis of IBS is based on specific 
criteria including recurrent abdominal pain or discomfort, relief with defecation, and change in stool 
frequency and appearance [61]. Diarrhea- (IBS-D) and constipation-predominant IBS (IBS-C) are the 
two primary subtypes of IBS, with a mixed subtype (IBS-M) occurring less frequently [60].  
Constipation and IBS are prevalent in North America, where they have been estimated to affect  
12–19% and 5–10% of the population, respectively, with a higher prevalence among females [62–66]. 
Both conditions are associated with a considerably reduced quality of life [67,68], elevated healthcare 
costs [69–71], and increased disability claims and work absenteeism, which place an economic burden 
on both patients and employers [72]. The first approach to treating these conditions is diet and lifestyle 
changes, including increasing exercise and dietary fiber intake [73,74]. Pharmacotherapy with 
prokinetic and antispasmodic agents are often utilized when lifestyle and dietary changes fail to 
alleviate symptoms [60]. However, while these agents provide brief symptomatic relief, they do not 
treat the underlying pathophysiology. 
2.3. Enterotoxin analogs for chronic constipation 
Linaclotide (MD-1100 acetate) is a synthetic 14-amino acid analogue of ST that binds to and 
activates GC-C and dose-dependently enhances gut secretion and motility in rodent models [75]. 
Furthermore, linaclotide has anti-nociceptive properties in rodent models of visceral hypersensitivity, 
indicating that the drug may both improve intestinal motility and discomfort in patients suffering from 
constipation [76]. In Phase I trials, linaclotide at single oral doses of 30–3000 μg or multiple doses of 
30–1000 μg was safe and well-tolerated with no evidence of systemic exposure [77,78]. In the first 
phase II randomized clinical trial (RCT) of linaclotide utility in the treatment of constipation, 
36 women with IBS-C were treated with oral linaclotide (100–1000 μg once daily). At a daily dose of 
1000 μg, linaclotide significantly decreased ascending colon emptying half-time (p = 0.015) and 
enhanced overall colonic transit at 48 hours (p = 0.02), while both doses accelerated the time to first 
bowel movement (p = 0.013), increased stool frequency (p = 0.037), decreased stool consistency  
(p < 0.001), and improved ease of stool passage (p < 0.001) without serious adverse effects [79]. In a 
follow-up study, 42 patients with chronic constipation were randomized to linaclotide (100, 300, or 




1,000 μg) or placebo once daily for two weeks. In this study, linaclotide produced a dose-dependent 
improvement in spontaneous bowel movement (SBM) frequency (p < 0.05), stool consistency scores, 
and straining scores, in addition to improving abdominal discomfort, severity of constipation, and 
overall relief with only mild-to-moderate GI side effects, predominantly diarrhea, being reported [80]. 
In a subsequent large, multi-center trial of 310 patients with chronic constipation treated with 
linaclotide (75–600 μg daily) for four weeks, all doses improved the weekly rate of spontaneous bowel 
movements (SBM) and complete spontaneous bowel movements (CSBM) in addition to improving 
stool consistency, straining, abdominal discomfort, bloating, and quality of life [81]. Finally, in a 
recent press release, Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc announced that, in 
two phase III trials of >600 patients with chronic constipation, 12 weeks of linaclotide therapy  
(133–266 μg per day) doubled average weekly CSBMs, tripled average weekly SBMs, and 
significantly improved bloating, abdominal discomfort, stool consistency, straining, and constipation 
severity (p < 0.001), with only minor GI side effects [38]. 
Currently, further trials of linaclotide therapy for the treatment of constipation are scheduled, and 
new drugs targeting the GC-C signaling axis for the treatment of chronic constipation and IBS-C are in 
preclinical development. Among these newer agents is SP-304, a synthetic analogue of the endogenous 
GC-C ligand, uroguanylin, and SP-333, a synthetic GC-C agonist (Synergy Pharmaceuticals Inc.). 
These agents are currently in preclinical trials for the treatment of GI diseases, including chronic 
constipation, IBS-C, and inflammatory bowel disease, and oral administration of SP-304 to rodents has 
been observed to both promote intestinal secretion and ameliorate GI inflammation [82]. 
2.4. Targeting GC-C in chronic inflammation 
Nitric oxide has anti-inflammatory effects, inhibiting leukocyte adhesion and oxidant production 
[83]. In that context, pharmacologic inhibitors of phosphodiesterases, which degrade cGMP, have 
beneficial effects in mouse models of inflammatory bowel disease [84,85]. Similarly, the uroguanylin 
analogue, SP-304, produces anti-inflammatory effects, associated with downregulation of  
pro-inflammatory cytokines including IL-4, IL-5, IL-23, and TNF, in mouse models of ulcerative 
colitis. Moreover, SP-304 also down-regulated cyclooxygenase-2 (COX-2) production of the 
inflammatory mediator prostaglandin E2 (PGE2)[82]. The inhibitory function of cGMP on 
inflammatory prostaglandin production may due to a decrease in intracellular arachidonic acid levels. 
Arachidonic acid, the precursor for prostaglandin synthesis, is liberated from membrane phospholipids 
via cleavage by phospholipase A2 (PLA2). Interestingly, PKG phosphorylates and inhibits PLA2 [86]. 
However, the precise mechanisms underlying the anti-inflammatory activity of SP-304 activation of 
GC-C remain to be determined (Figure 2). 
3. Targeting GC-C to Prevent Colorectal Cancer 
3.1. Dynamics of intestinal epithelial cells and crypt-villus homeostasis 
The intestinal epithelium lining the gastrointestinal tract is characterized by coordinated 
homeostatic programs comprising a developmental continuum integrating proliferation, differentiation, 
metabolic maturation and apoptosis along the crypt-villus axis. Crypts harbor stem cells at their base, 




which continuously regenerate progenitor cells destined to differentiate along secretory (goblet, 
Paneth, and enteroendocrine cells) or absorptive (enterocytes) lineages. This transition from 
proliferation to lineage commitment is associated with metabolic reprogramming from glycolysis to 
oxidative phosphorylation as the cells migrate toward the surface [87]. Metabolic reprogramming 
reflects the energy demands for different compartments, subserving the specific balance between 
proliferation and differentiation. In the crypt, cell division requires rapidly available energy supplies 
from glycolysis, while mitochondrially-mediated metabolism exploits the efficiency of ATP production 
by oxidative phosphorylation, supporting catabolic demands in mature cells in the differentiated 
compartment [88,89]. Following this transition, goblet, enteroendocrine cells and enterocytes continue 
to migrate to the tips of the villi and ultimately undergo apoptosis or anoikis [90–92]. In contrast, 
Paneth cells migrate down to the base of the crypt where they reside. The distinctive regenerative 
characteristic of the intestinal epithelium establishes a vertical axis representing a life cycle 
continuum, from cell birth to death. Dysregulation of this homeostatic process is intimately linked with 
intestinal tumorigenesis [89]. 
Enterocytes, comprising the majority of the intestinal epithelial monolayer, develop well-organized 
microvilli brush borders, containing key functional proteins mediating cognate digestive and 
absorptive functions [91]. Interspersed among enterocytes are the hormone-producing enteroendocrine 
cells, which comprise the largest endocrine system in the body in terms of both cell quantity and 
variety of hormones produced. Although enteroendocrine cells share biochemical similarities with 
neurons, they are derived from the same progenitor cells as other epithelial cells, originating from the 
endoderm. These cells secrete hormones supporting intestinal neuromuscular function, digestion, 
secretion, and central regulation of food intake as well as other systemic processes [93–98]. Goblet 
cells secrete mucin, which forms a mucus layer protecting intestinal surfaces and facilitating nutrient 
digestion and absorption by enterocytes [97]. Paneth cells, located only in small intestine, secrete 
antimicrobial peptides and growth factors into the lumen [99], forming a physical and functional 
barrier defending against bacterial invasion and intestinal tumorigenesis through innate immune 
responses [99].  
3.2. Enterotoxigenic signaling pathways and intestinal tumorigenesis 
There is an important functional relationship between circuits mediating enterotoxigenic signaling, 
intestinal homeostasis, and colorectal tumorigenesis that reflects co-option of critical physiologic cell 
pathways by bacteria. There is an under-appreciated inverse epidemiologic relationship between the 
prevalence of enterotoxigenic infections and colorectal cancer worldwide, and geographic regions that 
have the highest chronic colonization rates have the lowest rates of intestinal tumorigenesis  
(Figure 3)[100,101]. Also, guanylin and uroguanylin exhibit a pattern of expression along the  
crypt-villus axis that is associated with the transition from proliferating to differentiated 
compartments. These gene products are absent in the bottom of crypts (except Paneth cells in the small 
intestine) but present in the villus compartment in the small intestine and colonic surface epithelial 
cells (the mature enterocytes) (Figure 4)[14,59,102–105]. Additionally, guanylin and uroguanylin are 
the most commonly lost gene products in colorectal cancer, and their loss occurs early along the 
continuum of transformation [106–109]. Moreover, elimination of GC-C signaling increases the 




susceptibility of mice to intestinal tumorigenesis induced by carcinogens or inherited germline 
mutations [89,110] while, conversely, supplementation with uroguanylin decreases intestinal 
tumorigenesis in mouse models [101].  
Figure 3. World map comparing the prevalence of enterotoxigenic bacterial infections and 
colorectal cancer. This map highlights the inverse relationship between the prevalence of 
enterotoxigenic bacterial infections and incidence of colorectal cancer worldwide. The 
prevalence of enterotoxigenic infections is represented by the intensity of dots while the 
incidence of colorectal cancer is represented by color. Adapted from [97]. 
 
The effects of GC-C on normal crypt-villus dynamics and corruption of these mechanisms in 
tumorigenesis reflect a central role for cGMP and downstream effectors in coordinating intestinal 
epithelial cell homeostasis. GC-C activation inhibits proliferation of intestinal cells by prolonging the 
cell cycle through a cGMP-dependent mechanism. Hyperproliferation and acceleration of the epithelial 
cell cycle in GC-C deficient mice is associated with an increase in mediators promoting the G1/S 
transition (cyclin D1, pRb) and a decrease in cell cycle suppressors (p27), accompanied by hyperplasia 
of the crypt compartment, reflecting an increase in the number of progenitor cells. Also, mice deficient 
in GC-C signaling demonstrate an expansion of the proliferating crypt compartment [89] associated 
with a defect in differentiation with preferential commitment along the enterocytic, compared to the 
secretory, lineage [111]. Selective impairment in maturation of the secretory lineage reflects a role for 
GC-C in regulating intestinal cell differentiation by discrete molecular mechanisms, including 
interaction with transcription factors specifying secretory lineage commitment including Hes-1 and 
Math [111,112]. Elimination of GC-C expression also induces genomic instability in intestinal 
epithelial cells, increasing DNA double strand breaks, loss of heterozygosity, and point mutations in 
genes central to tumorigenesis, including APC and β-catenin [110]. Beyond accelerating the cell cycle 
and corrupting DNA damage sensing and repair, loss of GC-C signaling reprograms metabolism to the 
Warburg phenotype, directing ATP generation through aerobic glycolysis associated with a reduction 
in mitochondria and increases in reactive oxygen species which directly damage DNA [87,89,113]. 




Figure 4. GC-C signaling regulates homeostatic programs along the crypt-villus axis in the 
intestinal epithelium. The intestinal epithelium undergoes continuous regeneration and 
differentiation along the crypt-villus axis. Stem cells residing near the bottom of crypts 
give rise to rapidly proliferating progenitor cells, which subsequently differentiate into 
functional enterocytes. Guanylin and uroguanylin are secreted in a gradient along the 
crypt-villus axis, while guanylin is primarily secreted in colon and uroguanylin is mainly 
secreted in small intestine. Ligand activation of GC-C signaling reprograms proliferative 
and metabolic circuits in intestinal epithelial cells and ensures a homeostatic balance 
between proliferation and differentiation. Adapted from [84]. 
 
In the context of the established role of accumulated genetic alterations reinforcing genomic 
instability in carcinogenesis, loss of GC-C ligands early in tumorigenesis underscores the mechanistic 
contribution of dysregulated GC-C signaling in colorectal cancer. Mechanisms by which GC-C 
contributes to genomic integrity, including damage protection, detection and assessment, mutation 
repair, and the associated coordination of replicative decision-making are currently being explored. 
However, proliferative restriction and genomic quality control reflect reinforcing mechanisms by 
which GC-C opposes tumorigenesis [110]. Indeed, accelerated progression through G1 phase and 
premature entry into S phase are necessary for heritability and amplification of genetic instability 
[113,114]. Together, these observations suggest that GC-C is a lineage-specific tumor suppressor 
normally involved in the spatiotemporal patterning of the intestinal crypt-villus axis whose silencing, 
reflecting loss of expression of paracrine hormones, corrupts downstream processes universally 
underlying neoplastic transformation [87,89,100,110,115–117] Accordingly, colorectal tumorigenesis 
regulated by GC-C signaling suggests a novel pathophysiological paradigm in which colorectal cancer 
initiates, in part, as a disease of paracrine hormone insufficiency. 




3.3. GC-C paracrine hormone replacement to prevent colorectal cancer 
The novel roles of GC-C signaling in maintaining intestinal proliferative and metabolic homeostasis 
and suppressing intestinal tumorigenesis combined with the loss of GC-C ligands as an early event in 
intestinal neoplasia underscores a novel therapeutic paradigm for targeted colon cancer prevention and 
treatment through oral supplementation of GC-C ligands. Activation of the dormant tumor-suppressing 
receptor is anticipated to coordinately rescue cell cycle restriction and reprogram the Warburg 
glycolytic metabolic phenotype to inhibit intestinal tumorigenesis. Indeed, activation of GC-C 
signaling in human colon cancer cells inhibits cell proliferation by transient arrest of cell cycle and 
DNA synthesis, quantified by cell growth, colony formation, and 3H-thymidine incorporation 
[100,111,117,118]. GC-C signaling also induces a G1-S transition delay, quantified by flow cytometry 
and BrdU incorporation. This delay in cell cycle progression occurs in the absence of apoptosis, 
measured by TUNEL analysis and DNA laddering, or necrosis, determined by trypan blue exclusion 
and lactate dehydrogenase release. Cytostasis induced by GC-C ligands is specifically mediated by the 
accumulation of cGMP, as it is mimicked by the cell-permeant analog 8-Br-cGMP and reproduced and 
potentiated by the cGMP-specific phosphodiesterase inhibitor zaprinast, but not the inactive ST analog 
TJU1-103 [100–111,117]. Cytostasis induced by GC-C signaling is associated with altered expression 
of cell cycle mediators including cyclin D, pRb, and p27 regulating the transition through G1-S 
phase [89,100,111,117].  
Activation of GC-C signaling also reverts the tumorigenic Warburg metabolic phenotype in human 
and murine colon cancer cells. GC-C signaling inhibits glycolysis and fatty acid synthesis by reducing 
rate-limiting enzymes including glucose transporter 1, hexokinase, pyruvate kinase, acetyl-CoA 
carboxylase and acid citrate lyase, associated with a decrease in glucose uptake and lactate production. 
Further, activation of GC-C signaling in human colon cancer cells induces expression of critical 
transcription factors required for mitochondrial biogenesis, including PGC1α, mtTFA, and NRF1 [89]. 
Moreover, GC-C signaling promotes mitochondrial biogenesis by increasing mitochondrial content, 
associated with enhanced mitochondrial oxygen consumption, dehydrogenase activity and ATP 
production [89]. Reversion of the tumorigenic phenotype by GC-C is generalizable, reproduced in 
numerous human and mouse colon cancer cell lines [89]. Of significance, activation of GC-C signaling 
suppresses ROS (reactive oxygen species) production, reflecting increased function of the electron 
transport chain [119,120] or increased production of ROS scavengers [121,122], promoting genetic 
stability [89]. 
Interestingly, a study [101] using ApcMin/+ mice suggests that supplementation of an endogenous 
GC-C hormone, uroguanylin, in food and drinking water significantly suppresses intestinal 
tumorigenesis, including tumor multiplicity and tumor size in both small intestine and colon [101]. Of 
significance, this study suggests that induction of GC-C signaling prevents tumor initiation and 
progression by promoting apoptosis, rather than restricting cell proliferation. In that context, it is 
noteworthy that GC-C signaling prevents, rather than induces apoptosis in human colon cancer cells 
[123]. Thus, mechanisms underlying inhibition of tumorigenesis by uroguanylin administration remain 
unresolved [101,116,117]. 
In summary, these observations suggest that reconstitution of GC-C signaling in human colorectal 
cancer cells by replacing GC-C ligands inhibits cell proliferation through cGMP-dependent mechanisms 




by coordinated regulation of the cell cycle, metabolic circuits, chromosomal instability and/or cell 
death. In the context of universal hormone loss early in colorectal neoplasia, reconstitution of dormant 
receptor signaling by oral ligand supplementation may prevent initiation and progression of colon 
cancer [101] by opposing proliferation, metabolic reprogramming, and genomic instability [89,110]. 
4. Diagnostics and Therapeutics Targeted to GC-C for Metastatic Colorectal Cancer 
4.1. GC-C as a marker of metastatic colorectal cancer 
Constitutive expression of GC-C mRNA is universally retained throughout the transformational 
continuum in intestine, from adenoma to metastatic carcinoma [124]. Primary and metastatic tumors 
universally retain ST binding and cGMP production, in contrast to extra-intestinal tissues and tumors 
which do not express GC-C [15,125]. Further, GC-C expression in metastatic colorectal tumors was 
quantitatively similar to that in primary tumors, but in excess of normal colonic mucosa, quantified by 
immunohistochemistry [15,125]. Moreover, GC-C mRNA was identified in all primary and metastatic 
colorectal tumors, but not in extra-gastrointestinal tumors examined to date [124]. Universal  
over-expression of GC-C, at transcriptional and translational levels, by all primary and metastatic 
tumors arising from the colon and rectum, but not by extra-intestinal tumors, suggest that GC-C may 
be a unique biomarker for identifying and targeting metastatic colorectal cancer cells. Similarly, Gold 
and Freedman demonstrated in their seminal paper [126] that increased carcinoembryonic antigen 
(CEA) can be utilized as a biomarker for primary colon tumors. This elevated expression of CEA 
facilitates targeting with CEA-specific antibodies to colorectal tumors [127]. However, CEA is 
detectable in serum, while GC-C is normally absent in the circulation. Further, circulating CEA levels 
have been found in cigarette smokers, in patients with benign neoplasms, and in 15–20% of subjects 
with inflammatory disorders such as ulcerative colitis, Crohn's disease, pancreatitis, liver disease, and 
pulmonary infections. Such non-specificity renders CEA a less useful biomarker [128]. 
4.2. GC-C qRT-PCR as a molecular marker to stage patients with colorectal cancer 
The presence of tumor cells in regional lymph nodes is the single most important prognostic marker 
of survival in colorectal cancer patients [129,130]. Despite this established relationship, standard 
histopathologic lymph node screening remains imperfect and patients with node-negative (pN0, stage I 
and II) disease exhibit five year recurrence rates of ~25%, suggesting the presence of occult metastases 
in some patients [131]. Also, metastases in lymph nodes represent the principle predictive marker for 
identifying patients who benefit from adjuvant chemotherapy [132–136]. However, while treatment of 
stage III patients has been associated with improved survival, its utility in the pN0 population remains 
uncertain [131–139]. These observations emphasize the need for a more accurate assessment of occult 
metastases in the regional lymph nodes of pN0 colorectal cancer patients to improve current 
prognostic and therapeutic outcomes. 
The expression of GC-C is normally restricted to intestinal epithelia cells. However, its universal 
over-expression by colorectal cancer cells creates a unique opportunity to utilize the receptor as a 
biomarker for metastases [15,140,141]. Previous retrospective analyses demonstrated GC-C expression 
by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and its association with 




disease recurrence in pN0 patients [142]. These studies formed the basis for a recent trial prospectively 
exploring molecular analysis of GC-C by qRT-PCR in pN0 colorectal cancer patients to identify occult 
metastases and define prognostic risk [142]. Indeed, GC-C expression was detected in 87% of pN0 
patients, while 13% remained free of tumor cells. Further, 21% of GC-C-positive patients, but only 6% 
of GC-C-negative patients, developed recurrent disease. Indeed, patients who were GC-C-positive 
experienced a shorter time to recurrence and a decrease in disease-free survival compared to  
GC-C-negative patients. Moreover, GC-C qRT-PCR was the most powerful independent prognostic 
marker of risk for pN0 patients. This study suggests that molecular detection of occult metastases in 
lymph nodes from pN0 colorectal cancer patients employing GC-C qRT-PCR may improve staging 
precision and represent an important advancement for the prognostic and predictive management of 
patients with colorectal cancer. Indeed, the use of this technique in conjunction with established 
clinical staging modalities will enhance the treatment of patients by better defining individual risk and 
predicting the benefits of adjuvant chemotherapy. 
4.3. GC-C to deliver targeted diagnostics and therapeutics to metastatic colorectal cancer 
While primary tumors are effectively treated with surgical resection, only 39% of colorectal cancer 
cases are diagnosed prior to the cancer spreading from the primary site. Early stage patients enjoy a 
69% rate of survival over five years, while the five-year rate of survival for cases with distant 
metastasis upon diagnosis drops precipitously to 11.3% [143]. This direct relationship between occult 
metastases, which are present but undetected, at the time of diagnosis, and mortality highlights the 
unmet clinical need for effective imaging of colorectal cancer metastasis to improve the precision of 
diagnostic staging and identify patients who could derive benefit from adjuvant chemotherapy. It also 
underscores an essential future goal of developing targeted therapeutic agents that can eradicate 
metastatic cancer cells without impacting surrounding normal cells, an objective not yet achieved for 
colorectal cancer. In the context of diagnostic imaging, the current standard utilizes positron emission 
tomography (PET) to visualize enhanced glycolysis characterizing the Warburg metabolic phenotype 
in cancer. In that paradigm, 2-[18F]fluoro-2-deoxy-D-glucose (FDG) is taken up by tumors at a higher 
rate than surrounding normal tissues. While this differential uptake supports PET imaging, limited 
sensitivity and specificity reflect the dependency of all cells on glucose metabolism. 
Advanced technology platforms for imaging seek targeted receptor-based molecular probes, rather 
than metabolic detectors, to improve the sensitivity and specificity of metastatic tumor detection 
[144,145]. In the context, ST conjugated to a radionuclide retains full potency for GC-C binding, and 
differential accumulation in subcutaneous and hepatic human colon tumors expressing GC-C, but not 
in other tissues or tumors that do not express GC-C, can be visualized by gamma camera scintigraphy 
with extremely high sensitivity and specificity [146–153]. Advantages conferred by specific 
expression of GC-C only in metastatic tumors in extra-intestinal sites is remarkably enhanced by 
endocytosis of this receptor following ligand binding [146,153]. Beyond rapid internalization, 
endocytosis of GC-C deposits cognate ligands and their payloads in the intracellular compartment, 
after which these receptors recycle back to the surface [146,153]. Thus, continuous exposure to ligand 
conjugates, for example in the circulation, permits extended accumulation of their payloads 
intracellularly in tumors, magnifying highly selective diagnostic and therapeutic exposures beyond that 




achieved by cell surface binding alone [146,153]. Moreover, amplification provided by intracellular 
accumulation can be further enhanced by employing polyvalent targeting agents, for example,  
GC-C-directed antibodies modified to carry multiple diagnostic and/or therapeutic agents. In the 
context of the universal expression of GC-C in colorectal tumors [124,140,142,154], these 
observations underscore the future utility of GC-C-directed ligands for both detecting and treating 
metastatic disease. 
4.4. GC-C-targeted colorectal cancer vaccines 
Inducing active immune responses against tumors through vaccination has emerged as an attractive 
adjuvant approach for secondary prevention of cancer. One major challenge in developing cancer 
vaccines has been the identification of suitable tumor antigens that can be recognized by the host 
immune system. Ideally, target antigens would be entirely tumor-specific, mediating recognition and 
elimination by the immune system without collateral autoimmunity in normal tissues. However, 
tumors arise from normal tissues and, consequently, express self antigens subject to mechanisms of 
tolerance which prevent both autoimmunity and antitumor immunity [155]. 
Thus, tumor vaccine strategies have targeted self-proteins employing a variety of strategies. 
Oncogenic transformation results from mutation of self proteins, which may provide an 
immunologically unique (“foreign”) tumor target [156]. Also, oncofetal antigens, which are only 
expressed during fetal development, may be ectopically expressed after tumor transformation [157]. 
Similarly, some tumors ectopically express cancer testis antigens, which are normally found only in 
immune privileged sites, limiting tolerance to these antigens. However, expression of these antigens is 
rare in epithelial tumors, requiring screening and production of individualized cancer vaccines. 
Alternatively over-expressed self-antigens including Her2/neu, Mucin-1, EpCAM, and CEA have been 
targeted in cancer vaccination strategies [158–160]. Indeed, a modest clinical impact has been 
achieved by targeting CEA-expressing colorectal tumors in conjunction with immunostimulatory 
adjuvants. However, the requirement for adjuvants reveals suboptimal responses to antigen alone, 
which may reflect central tolerance to self antigens [161]. In fact, expression of many tumor-associated 
self antigens can be widespread in normal tissues, substantially hindering immune responses to them. 
Further, expression of these antigens in normal tissues also may enhance immune related toxicities 
produced by these vaccines. For example, 10% of patients immunized with a multi-peptide melanoma 
vaccine developed vitiligo [162]. 
In contrast to conventional antigens, a recently established class of tumor targets, cancer mucosal 
antigens (CMAs), may be ideal for directed treatment of metastatic cancer. CMAs are expressed 
exclusively in mucosal tissues, such as the intestinal epithelium, and in tumors derived therein, such as 
colorectal cancer. Importantly, separation of mucosal and systemic immune responses, reflecting 
physical and functional barriers, limits immunological cross-talk between compartments [163,164]. 
Indeed, lymphocyte activation imprints immune cells with chemokine receptor and adhesion molecule 
expression that retain them in the compartment of activation. For example, T cells activated in  
skin-draining lymph nodes by Langerhans cells up-regulate CCR4 and E-selectin ligand expression 
resulting in homing to inflamed skin [165]. In that regard, potential deficits in systemic tolerance 
toward CMAs, based on their confinement to the mucosal compartment, permit generation of  




CMA-specific immune responses following systemic immunization. These immune responses may 
augment anti-tumor immunity with limited autoimmunity due to the inability of systemically activated 
cells to traffic to the mucosal compartment [87,166,167]. 
GC-C is the first identified CMA and its normal restriction to the mucosal compartment might 
permit the generation of GC-C-specific systemic immunity due to attenuated systemic tolerance. 
Moreover, the universal expression of GC-C in tumors arising from the colon and rectum 
[124,142,154] may make it an ideal target for effective immunotherapy in all patients. Indeed, 
preclinical mouse models have demonstrated that mice generate anti-GC-C immune responses when 
primed with a recombinant adenoviral vaccine expressing the extracellular domain of GC-C. 
Prophylactic immunization with adenovirus expressing GC-C inhibited tumor growth and prolonged 
survival in parenchymal lung and liver metastases models [168,169]. Analysis of vaccine-induced 
immune responses revealed lineage-specific systemic tolerance to GC-C. Immunization induced  
GC-C-specific CD8+ T cell, but not GC-C-specific CD4+ T cell or antibody responses, in wild-type 
mice. In contrast, immunization of mice in which GC-C expression was eliminated (GC-C−/−) induced 
GC-C-specific CD8+ T cell, CD4+ T cell, and antibody responses. Induction of all arms of the adaptive 
immune system in GC-C−/− mice indicates an incomplete systemic tolerance in wild type animals, in 
which only GC-C specific CD8+ T cells circumvent toleragenic mechanisms [169]. In contrast,  
GC-C-specific CD4+ T cells are targets of systemic tolerance in wild-type mice and may be deleted 
during thymic development, differentiate into immunosuppressive regulatory T cells, or rendered 
anergic in the periphery.  
The generation of GC-C-specific immunity in mice did not produce serum anti-nuclear antibodies 
or enhancement of immune infiltrates into gastrointestinal tissues [169]. Moreover, maximal GC-C 
specific CD8+ T cell responses generated through heterologous prime-boost vaccination did not 
exacerbate autoimmunity in a chemically-induced mouse model of inflammatory bowel disease or 
augment tumorigenesis in colitis-associated or genetic models of colorectal cancer [168]. These 
observations reinforce the hypothesis that GC-C-specific immunization can promote anti-tumor 
efficacy without autoimmunity [168]. The absence of autoimmunity likely reflects immune 
compartmentalization, which limits trafficking of systemically activated immune cells to the mucosal 
compartment. Systemic immunization producing effective immune responses in the systemic 
compartment fails to produce mucosal responses protecting the gastrointestinal tract from  
GC-C-specific autoimmunity [170]. Additional studies characterizing the mechanisms of tolerance in 
wild type facilitate the development of next-generation vaccines that optimally activate all branches of 
the adaptive immune response in order to achieve maximal anti-tumor immunity targeted to cancer 
mucosal antigens. 
5. Conclusions 
The ability of toxins to co-opt normal physiological pathways to produce pathophysiological 
consequences can be exploited to explore the fundamentals of cell biology and mechanisms of disease. 
Thirty years after identification of bacterial heat-stable enterotoxins, their study has revealed the novel 
receptor GC-C and its two endogenous paracrine hormones, guanylin and uroguanylin, and decoded 
signaling pathways regulating intestinal homeostasis. These studies have identified novel therapeutic 




and preventive strategies for colorectal cancer, chronic constipation, and inflammatory bowel disease. 
Furthermore, universal retention of GC-C expression in colorectal tumors offers a unique target for 
diagnosis, therapy, and vaccine development. The emerging understanding of heat-stable enterotoxins, 
beyond their induction of diarrheal disease, uniquely exemplifies success in translational research 
across the continuum from the laboratory bench, to the bedside and beyond to patient populations. 
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